Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Koh

Showing results (101-110 of 144) with videos related to

Pageof 15
Sort By:
American Journal of Clinical Oncology|December 6, 2012
The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapyHiroaki Akamatsu, Kyoichi Kaira, Haruyasu Murakami, et al.
BMC Cancer|October 29, 2014
Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assaysHirotsugu Kenmotsu, Masakuni Serizawa, Yasuhiro Koh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2022
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohortKenji Sawa, Yasuhiro Koh, Tomoya Kawaguchi, et al.
Scientific Reports|March 12, 2021
Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factorsMotohiro Izumi, Jun Oyanagi, Kenji Sawa, et al.
BMC Cancer|November 9, 2016
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patientsRyo Ko, Hirotsugu Kenmotsu, Masakuni Serizawa, et al.
Cancer|April 5, 2014
Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute studyMasakuni Serizawa, Yasuhiro Koh, Hirotsugu Kenmotsu, et al.
Investigational New Drugs|January 9, 2025
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNAYoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, et al.
BMJ Open|September 10, 2020
Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in JapanKoichi Ogawa, Yasuhiro Koh, Hiroyasu Kaneda, et al.
International Journal of Hematology|April 15, 2021
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patientsMorio Matsumoto, Kenshi Suzuki, Junya Kuroda, et al.
Pageof 15

Showing results (101-110 of 144) with videos related to

Sort By:
Pageof 15
American Journal of Clinical Oncology|December 6, 2012
The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapyHiroaki Akamatsu, Kyoichi Kaira, Haruyasu Murakami, et al.
BMC Cancer|October 29, 2014
Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assaysHirotsugu Kenmotsu, Masakuni Serizawa, Yasuhiro Koh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2022
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohortKenji Sawa, Yasuhiro Koh, Tomoya Kawaguchi, et al.
Scientific Reports|March 12, 2021
Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factorsMotohiro Izumi, Jun Oyanagi, Kenji Sawa, et al.
BMC Cancer|November 9, 2016
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patientsRyo Ko, Hirotsugu Kenmotsu, Masakuni Serizawa, et al.
Cancer|April 5, 2014
Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute studyMasakuni Serizawa, Yasuhiro Koh, Hirotsugu Kenmotsu, et al.
Investigational New Drugs|January 9, 2025
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNAYoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, et al.
BMJ Open|September 10, 2020
Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in JapanKoichi Ogawa, Yasuhiro Koh, Hiroyasu Kaneda, et al.
International Journal of Hematology|April 15, 2021
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patientsMorio Matsumoto, Kenshi Suzuki, Junya Kuroda, et al.
Pageof 15